ArticleScientific reports2025
Integration of transcriptomics and metabolomics reveals the mechanism of Lycium barbarum polysaccharides inhibited MCF-7 cell proliferation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Breast cancer, as a highly prevalent malignant tumor among women, has a consistently high mortality rate due to metastasis and drug resistance. Lycium barbarum polysaccharides (LBP), which have been reported to have significant anti-tumor activity, have not yet had their molecular mechanism and signaling pathways against breast cancer clearly defined. In this study, the CCK-8 experiment determined that 8 mg/mL LBP treatment for 48 h was the optimal condition for subsequent transcriptomics and metabolomics analyses. The results demonstrated that a high concentration of LBP significantly reduced the viability of MCF-7 cells and inhibited cell proliferation. Transcriptome sequencing revealed that LBP markedly altered the expression levels of the genes HO-1, FTH1, FTL, and TFRC. Metabolomics analysis further indicated that LBP significantly impacted glutathione metabolism, glycerophospholipid metabolism, and the alanine-aspartate-glutamate metabolic pathway. Further integration of transcriptomic and metabolomic data suggests that LBP may suppress cell proliferation by activating the ferroptosis pathway via the NRF2/HO-1 axis. To further validate this hypothesis, we conducted additional experiments to detect the NRF2/HO-1 signaling pathway and markers associated with ferroptosis. The results demonstrated that LBP treatment significantly upregulated the expression of NRF2 and its downstream effector molecule HO-1. Moreover, the specific NRF2 inhibitor ML385 was able to reverse the alterations in GSH, Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.